{"id":45806,"date":"2022-07-05T13:01:42","date_gmt":"2022-07-05T11:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kalvista-pharmaceuticals-presents-new-data-for-sebetralstat-and-its-oral-factor-xiia-inhibitor-program\/"},"modified":"2022-07-05T13:01:42","modified_gmt":"2022-07-05T11:01:42","slug":"kalvista-pharmaceuticals-presents-new-data-for-sebetralstat-and-its-oral-factor-xiia-inhibitor-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kalvista-pharmaceuticals-presents-new-data-for-sebetralstat-and-its-oral-factor-xiia-inhibitor-program\/","title":{"rendered":"KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program"},"content":{"rendered":"
\n

\n\u2013 Sebetralstat data examines efficacy by attack location and population PK comparisons \u2013<\/i>\n<\/p>\n

\n\u2013 Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system –<\/i>\n<\/p>\n

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV<\/a>–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, has presented data for its oral on demand plasma kallikrein (PKa) inhibitor and Factor XIIa (FXIIa) programs at the EAACI2022 conference in Prague, Czech Republic.\n<\/p>\n

<\/a><\/p>\n

\nKalVista presented data showing sebetralstat was an effective treatment for both peripheral and abdominal attacks with 80% of attacks achieving symptom relief within 12 hours, regardless of attack location. Population pharmacokinetic (PK) data showed that the PK of sebetralstat did not appear to be affected by consumption of a normal meal prior to dosing compared with taking the dose after fasting. Furthermore, PK modeling supports the use of sebetralstat in adolescents 12 years and older without dose adjustment.\n<\/p>\n

\nAnimal model data with oral FXIIa inhibitor KV998086 showed the compound protected mice from kallikrein-kinin system (KKS) mediated edema. KV998086 blocked the generation of FXIIa & PKa and prevented HK cleavage in a dose-responsive manner. Pharmacokinetic studies showed that oral KV998086 displayed high bioavailability. Inhibition of the KKS with KV998086 may provide an opportunity for once-daily HAE prophylaxis as well as having potential to treat other KKS-mediated diseases.\n<\/p>\n

\n\u201cThe population PK study is important for our sebetralstat program,\u201d said Andrew Crockett, Chief Executive Officer of KalVista. \u201cIt expands the population we can target for treatment in our Phase 3 KONFIDENT trial without having to use multiple dose regimens. Additionally, the preclinical data with our oral FXIIa inhibitor once again shows the promise of this novel class of compounds, which will be important to our company\u2019s future even beyond HAE.\u201d\n<\/p>\n

\nThe following presentations occurred at EAACI2022:\n<\/p>\n